Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) has announced the granting of inducement awards under its 2023 Inducement Plan. The company granted stock options to purchase up to 124,000 shares of common stock to six new employees on February 1, 2025. These stock options follow a four-year vesting schedule, with 25% of shares vesting after the first year, followed by monthly vesting of 1/48th of the underlying shares over the subsequent 36 months. The vesting is contingent upon continued employment with Syndax.
Syndax Pharmaceuticals (SNDX) ha annunciato il conferimento di premi di induzione nell'ambito del suo Piano di Induzione 2023. L'azienda ha concesso opzioni su azioni per acquistare fino a 124.000 azioni ordinarie a sei nuovi dipendenti il 1° febbraio 2025. Queste opzioni su azioni seguono un programma di maturazione di quattro anni, con il 25% delle azioni che matura dopo il primo anno, seguito da una maturazione mensile di 1/48 delle azioni sottostanti nei successivi 36 mesi. La maturazione è subordinata al mantenimento dell'impiego presso Syndax.
Syndax Pharmaceuticals (SNDX) ha anunciado la concesión de premios de inducción bajo su Plan de Inducción 2023. La compañía otorgó opciones sobre acciones para comprar hasta 124.000 acciones ordinarias a seis nuevos empleados el 1 de febrero de 2025. Estas opciones sobre acciones siguen un calendario de adquisición de cuatro años, con el 25% de las acciones adquiriendo derechos después del primer año, seguido por adquisiciones mensuales de 1/48 de las acciones subyacentes durante los siguientes 36 meses. La adquisición está sujeta a la continuación del empleo en Syndax.
신닥스 제약 (SNDX)은 2023 유도 계획에 따라 유도 보상을 부여한다고 발표했습니다. 회사는 2025년 2월 1일에 6명의 새로운 직원에게 최대 124,000주의 보통주를 구매할 수 있는 주식 옵션을 부여했습니다. 이러한 주식 옵션은 4년의 경과 일정에 따라 진행되며, 25%의 주식은 첫 해가 끝난 후에 귀속되고, 이후 36개월 동안 매달 1/48의 주식이 귀속됩니다. 귀속 조건은 신닥스에서의 계속적인 고용에 달려 있습니다.
Syndax Pharmaceuticals (SNDX) a annoncé l'octroi de récompenses d'incitation dans le cadre de son Plan d'incitation 2023. La société a accordé des options d'achat d'actions pour acquérir jusqu'à 124.000 actions ordinaires à six nouveaux employés le 1er février 2025. Ces options d'achat d'actions suivent un calendrier d'acquisition de quatre ans, avec 25% des actions acquises après la première année, suivies d'une acquisition mensuelle de 1/48 des actions sous-jacentes au cours des 36 mois suivants. L'acquisition est conditionnelle à un emploi continu chez Syndax.
Syndax Pharmaceuticals (SNDX) hat die Gewährung von Induktionsauszeichnungen im Rahmen seines Induktionsplans 2023 angekündigt. Das Unternehmen gewährte am 1. Februar 2025 sechs neuen Mitarbeitern Aktienoptionen zum Kauf von bis zu 124.000 Aktien des Stammkapitals. Diese Aktienoptionen folgen einem vierjährigen Vesting-Plan, wobei 25% der Aktien nach dem ersten Jahr, gefolgt von einer monatlichen Zuteilung von 1/48 der zugrunde liegenden Aktien über die folgenden 36 Monate, geboten werden. Das Vesting ist von der fortgesetzten Beschäftigung bei Syndax abhängig.
- Stock-based compensation aligns employee interests with shareholders
- Expansion of workforce indicates company growth with six new hires
- Potential shareholder dilution from 124,000 new shares
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302367038.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
How many shares were granted in Syndax's (SNDX) February 2025 inducement awards?
What is the vesting schedule for SNDX's February 2025 inducement stock options?
How many employees received SNDX stock options in the February 2025 grant?
When did Syndax Pharmaceuticals (SNDX) issue its February 2025 inducement grants?
